Document Detail

Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
MedLine Citation:
PMID:  18602948     Owner:  NLM     Status:  MEDLINE    
The polycystic ovary syndrome (PCOS) affects 5-10% of all premenopausal women. It is diagnosed by a combination of oligo-amenorrhea and hyperandrogenism (NIH criteria) or by the presence of two out of three of: oligo-amenorrhea, hyperandrogenism, polycystic ovaries on ultrasound (Rotterdam criteria). PCOS is associated with obesity, insulin resistance and dyslipidemia. Different patterns of dyslipidemia can be present, both in lean and obese PCOS. Low HDL-cholesterol, with or without elevated TG, is the most prominent lipid abnormality. In addition, smaller HDL and LDL particles and elevated postprandial TG responses are reported. Hyperandrogenism, anovulation and insulin resistance affect multiple steps in lipid metabolism in PCOS, as will be discussed. Surrogate markers for atherosclerosis are consistently abnormal in PCOS, while studies on clinical CVD endpoints are limited and non-conclusive. The (pharmaco-) therapy of dyslipidemia in PCOS will be discussed. In addition, the effects of other PCOS related (pharmaco-) therapies, primarily aimed at hyperandrogenism, anovulation or insulin resistance, on lipid metabolism will be addressed.
H E Westerveld; M Hoogendoorn; A W F de Jong; A J Goverde; B C J M Fauser; G M Dallinga-Thie
Related Documents :
17003308 - Low testosterone and high c-reactive protein concentrations predict low hematocrit in t...
1623148 - Hyperandrogenism: new insights into etiology, diagnosis, and therapy.
9798138 - Insulin and polycystic ovary syndrome: a new look at an old subject.
17454168 - Metformin administration is more effective when non-obese patients with polycystic ovar...
10444418 - Arterial kic as marker of liver and muscle intracellular leucine pools in healthy and t...
2261838 - Diabetic cardiomyopathy.
Publication Detail:
Type:  Journal Article; Review     Date:  2008-06-17
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  119     ISSN:  0163-7258     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-08     Completed Date:  2009-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  223-41     Citation Subset:  IM    
Department of Internal Medicine, University Medical Center Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anovulation / complications,  drug therapy,  metabolism
Dyslipidemias / complications,  drug therapy,  metabolism
Hyperandrogenism / complications,  drug therapy,  metabolism
Models, Biological
Polycystic Ovary Syndrome / complications,  drug therapy*,  metabolism*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impaired energetics in heart failure - a new therapeutic target.
Next Document:  Adeno-associated virus-mediated ILK gene silencing in the rat NAc core.